BioNTech SE (NASDAQ:BNTX)
| 112.76 Delayed Data As of Oct 02 |  +4.12 / +3.79%Today’s Change | 95.50 Today|||52-Week Range 188.99 | -24.94% Year-to-Date |
Latest BNTX News | Press Releases
| 3 Stocks to Buy in October That Could Soar More Than 40% Over the Next 12 Months, According to Wall Street Oct 01 / MotleyFool.com - Paid Partner Content | Undervalued Biotech Stocks Shine: Pfizer and BioNTech Show Robust Resilience Sep 28 / GuruFocus News - Paid Partner Content |
| Why Pfizer and BioNTech Stocks Zoomed Higher Today Sep 29 / MotleyFool.com - Paid Partner Content | Undervalued Biotech Stocks Shine: Pfizer and BioNTech Show Resilience Sep 28 / GuruFocus News - Paid Partner Content |
| Why CureVac Stock Plunged Today Sep 29 / MotleyFool.com - Paid Partner Content | With New COVID-19 Boosters in Tow, Which Is the Better Buy: Pfizer, BioNtech, or Moderna Stock? Sep 20 / MotleyFool.com - Paid Partner Content |
Today’s Trading
| Previous close | 108.64 |
| Today’s open | 108.57 |
| Day’s range | 108.24 - 113.04 |
| Volume | 51,404 |
| Average volume (3 months) | 670,334 |
| Market cap | $26.1B |
Data as of 3:59pm ET, 10/02/2023
Growth & Valuation
| Earnings growth (last year) | -18.26% |
| Earnings growth (this year) | -87.32% |
| Earnings growth (next 5 years) | -57.02% |
| Revenue growth (last year) | -18.89% |
| P/E ratio | 6.0 |
| Price/Sales | 2.06 |
| Price/Book | 1.24 |
Competitors
| No competitors data available. |
Financials
| Next reporting date | November 6, 2023 |
| EPS forecast (this quarter) | $1.09 |
| Annual revenue (last year) | $18.2B |
| Annual profit (last year) | $9.9B |
| Net profit margin | 54.50% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters --, -- |
Forecasts
